div.javascriptErrorPage { background-color: rgba(0,0,0,0.3); width: 100%; text-align: center; height: 100vh; } div.javascriptErrorPageContent { position: fixed; top : 50%; left: 50%; -ms-transform: translate(-50%, -50%); transform : translate(-50%, -50%); border-radius: 20px; background: #FFFFFF; box-shadow: 0px 3px 5px rgba(0, 0, 0, 0.2), 0px 6px 10px rgba(0, 0, 0, 0.14), 0px 1px 18px rgba(0, 0, 0, 0.12); } /* This is mobile */ @media (max-width:600px) { div.javascriptErrorPage { background-color: none; width: 100%; text-align: center; height: auto; } div.javascriptErrorPageContent { width: 100%; border-radius: none; box-shadow: none; } }

JavaScript required

We’re sorry, but WorldCat does not work without JavaScript enabled. Please enable JavaScript on your browser.

Peer-reviewed

Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy

Summary:Pathological cardiac remodelling and subsequent heart failure represents an unmet clinical need. Long non-coding RNAs (lncRNAs) are emerging as crucial molecular orchestrators of disease processes, including that of heart diseases. Here, we report on the powerful therapeutic potential of the conserved lncRNA H19 in the treatment of pathological cardiac hypertrophy

Article, 2020